Nina Rawal, Trill Impact Ventures, on the investment in Cinclus Pharma
Highlights from the 2024 Annual Report: Interview with Nina Rawal.
Trill Impact Ventures views Cinclus Pharma as a strong Life Science candidate with the potential to address unmet medical needs in GERD and H. pylori. Nina Rawal, Co-Head of Ventures and a board member at Cinclus Pharma, contributes her biomedical expertise and financing experience.
”Trill Impact focuses on commercial investments that promote the UN’s global goals for sustainable development. The venture strategy within Trill Impact, which Nina leads, focuses on life science and green transition. Cinclus Pharma’s drug candidate, linaprazan glurate, has the potential to significantly improve treatment of GERD and Heliobacter pylori (H. pylori). WHO lists H. pylori as a major threat to global health, and combination therapies involving linaprazan glurate could reduce antibiotic use for H. pylori. The opportunity to treat two major public diseases further strengthens our excitement about the company.”
Nina highlights the importance of expanding access to treatments globally and addressing the gap for underserved patient groups. Finding ways to tap into the 6 billion patients across middle income countries, is a business opportunity.
”An important part of our contribution is to support Cinclus in closing the access gap for underserved patient categories.”
Trill Impact further supports Cinclus in making strategic decisions to achieve drug registration and create long-term value.
”The Cinclus team brings a unique advantage, having spearheaded the development and launch of earlier acid control drugs while at AstraZeneca, a former leader in the GI therapeutic area. This deep-rooted experience is invaluable as Cinclus continues its own journey towards commercialization. We believe Cinclus has significant potential to impact the treatment of eGERD and H. Pylori, and we look forward to continuing this exciting journey together.”